step 6 semaglutide Efficacy and safety of once-weekly 2·4 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial The Potential of Semaglutide Once-Weekly

The largest psychiatric meta-analysis to date 80 randomized controlled trials, over 107,000 patients also found significant improvements in restrained eating and emotional eating with GLP-1 medications compared to placebo ( Pierret et al., JAMA Psychiatry, 2025 )

BMI between the ranges of 27-30 kg/m2 with existing comorbidities like diabetes, hypertension, hyperlipidaemia, obstructive sleep apnoea (OSA), heart attack, stroke, blood vessel disorders

Seek prompt review for new or worsening visual symptoms, which could indicate changes in diabetic retinopathy

Q6: Who shouldnt use GLP-1s

Frequently asked questions What is levocarnitine